
Overview
Perrigo Q3 2025 net sales down 4.1%, missing analyst expectations
Adjusted EPS for Q3 2025 beats analyst estimates
Company updates FY 2025 outlook due to industry dynamics and market trends
Outlook
Perrigo revises 2025 outlook due to infant formula dynamics and soft OTC trends
Company expects 2025 adjusted EPS of $2.70 to $2.80, up 5% to 9%
Perrigo forecasts 2025 net sales growth of -2.5% to -3.0%
Result Drivers
OTC MARKET SHARE GAINS - Perrigo achieved dollar, unit, and volume share gains in five of seven OTC store brand categories despite soft market consumption trends
STRATEGIC BUSINESS REVIEWS - Ongoing strategic reviews of Infant Formula and Oral Care businesses, with a focus on portfolio evaluation
CURRENCY AND COST MANAGEMENT - Favorable currency translation and disciplined cost management partially offset declines in adjusted operating income
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Miss | $1.04 bln | $1.09 bln (3 Analysts) |
Q3 Adjusted EPS | Beat | $0.80 | $0.75 (3 Analysts) |
Q3 EPS |
| $0.09 |
|
Q3 Adjusted Operating Income | Beat | $173 mln | $168.60 mln (3 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Perrigo Company PLC is $32.00, about 36.9% above its November 4 closing price of $20.19
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nPn6XplXha
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.